FirstWord: Market Research Reports

... of warfarin) with Xarelto retaining its current level of market share. Bayer's confidence in Xarelto is clearly high, adds Leuchten, pointing to the ... this week's Physician Views poll revisits the novel anticoagulant market and surveys cardiologists and general practioners/primary care physicians (GP/PCPs) ...

... early stages of being coordinated into a system across Europe. In The Reality of Market Access in Europe: the role of Health Technology Assessment, FirstWord skilfully addresses ... Benefits Attitudes to drug reimbursement have been shaped by economics. In The Reality of Market Access in Europe: the role of Health Technology Assessment, you will: Understand ...

... will provide payers to extract greater discounting and rebates – will also play a role in market development. Nevertheless, AstraZeneca is hoping that a new pen device will ... and/or patient preference towards this drug class as a whole? What advantage they perceive would be provided by an auto-injector pen ...

... available (its approval in the US market is anticipated in Q3). Predicting an accurate view of future market dynamics remains difficult at this point, however ... expect to prescribe a once-weekly product with comparable efficacy to Victoza (i.e. dulaglutide) if that product had: A comparable weight-loss profile; ...

... term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels ... comprehensive FirstWord research is available in two comprehensive modules: The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive ...

... accounted for around 70 percent of usage to date. Genotype 1 patients are viewed as being a key population for all-oral therapies (which dispense ... availability may have on new patient diagnosis rates. This week's Physician Views poll asks US and EU-based gastroenterologists, hepatologists and infectious disease ...

... pharma companies truly integrating health outcome values into product development or merely paying lip-service? In a rare and comprehensive insight into thriving in the "Outcomes Era", Value-driven Pharma: Integrating health outcomes across ... been shaped by economics. In Value-driven Pharma: Integrating health outcomes across the product lifecycle, you will: Understand the importance of endorsing a comprehensive approach to health outcomes from the earliest ...

... all of the ‘low hanging fruit’ have been taken there is another perspective: that there is plenty of fruit left on the tree and companies ... company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment ...

... opinion This new KOL Insight report Breast Cancer –new targeted therapies transform treatment provides everyone interested in this dynamic cancer sector with a complete understanding of the targeted products ... and weaknesses of currently available targeted therapies for breast cancer Assess how prescribing trends will change with launch of new products Identify promising late-stage ...

... what do physicians think? What do they consider to be the correct naming convention and how will this impact their potential usage of biosimilars. This week's Physician Views poll will ask US and EU5-based oncologists and rheumatologists: What naming convention for biosimilar products they believe ...

... using it for a long time with no real safety issues." How neurologists utilise any generic version of Copaxone, should one or multiple ... about potential usage of such a product. This week's Physician Views poll will ask US-based neurologists: Approximately what percentage of existing Copaxone patients do you ...

... to drive a notable shift in the Indian trastuzumab market, this week's Physician Views poll asks Indian oncologists to provide their initial views on what its availability will ... drug) or across the HER2-positive breast cancer treatment paradigm? How confident they are in using CANMAb given the relative size ...

... a notable caveat could be that it is waiting to step up promotion of Breo when it launches a second new COPD drug – Anoro Ellipta – which was approved ... has delivered lower-than-expected uptake since launching in late 2013, this week's Physician Views poll will ask US-based pulmonologists: Approximately how ...

... to be seen if Farxiga can find a suitable position in Invokana's slipstream. While physicians have embraced the SGLT-2 class – with sizeable usage reported ... to side-effect concerns) could also limit uptake. Nevertheless, with momentum growing for the SGLT-2 class, there could be an opportunity for AstraZeneca ...

... is changing. In Designing Clinical Trials to Show Value, you will: Understand how new concepts of value created by cost-conscious healthcare stakeholders are transforming clinical development programmes ... Understand new trends in clinical trials that promise to deliver product value sought by regulators, health systems and patients Designing Clinical Trials to Show Value answers key questions ...

... . This report breaks down KAM requirements and lets you build the team you need. This new report Effective Pharma KAM Teams – the essential factors driving performance provides everyone involved with building running or implementing KAM ...

... high cost of orphan drugs. International and regional regulations are also hurdles to be overcome, despite harmonisations efforts by agencies. In Market Access for Orphan Drugs: Assessing the Global Landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the ...

... effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that ... significant market event. Key Benefits Therapy Trends Consensus Outlook: Hepatitis C provides: Evaluate future sales forecasts and predicted market growth ...

... radiopharmaceutical - see In Focus: Bayer's M&A catalyst – FirstWord speaks to Xofigo's lead investigator. Impressive Q3 sales, and confirmation that Bayer and Algeta ... gain a better understanding of the outlook for Xofigo, this week's Physician Views poll will ask US-based urologists and oncologists... Where ...

... hypoglycaemia – currently known as Insulin U300 – is the most important product in Sanofi's late-stage R&D pipeline. With submission to regulators expected next year ... in selected European markets and Japan – there appears to be an opportunity for Sanofi to push home an advantage with U300, particularly by building on the entrenchment ...

... currently anticipated for AbbVie. To gain a better perspective on how physicians expect to use interferon-free regimens, FirstWord is polling gastroenterologists/hepatologists and infectious ... of genotype 1 patients they would prescribe an interferon-sparing, once-daily, single-tablet therapy rather than an interferon-sparing multi-tablet therapy dosed ...

... mixed opinions on the commercial opportunity, but one of the more intriguing near- ... the US within the next few months, this week's Physician Views poll targets general practitioners and internal ... obesity (and based on available Phase III data), in what percentage of obese patients would you consider prescribing ...

... for Gazyva are ongoing. This week’s FirstWord Physician Views poll aims to gauge initial oncologist reaction to the data for, and approval of, Gazyva and ... uptake will occur in the first-line CLL setting. Specifically oncologists based in the US and EU5 will be asked: What percentage of chronic ...

... the global prostate cancer market to grow from $3.5 billion in 2012 to $7.7 billion in 2017. Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top analyses the global prostate cancer market players ... data analysis updates over the next 12 months Report Benefits: Consensus Outlook: Prostate Cancer – Competition intensifies in race to the top will allow you to: Evaluate future ...

... world in biosimilar sales. Although the European experience differs markedly from the anticipated evolution of biosimilars in the US, there are lessons to be learned. In Commercialisation of Biosimilars: strategies for ... of how to design strategies to influence key opinion leaders Understand why biosimilar acceptance is slower than most new generic drugs Commercialisation of Biosimilars: strategies for market penetration ...

... opinion leader feedback. Similarly, there is evidence to support the view that anticipation among European neurologists is equally high. When ... Delayed launch for Biogen Idec's Tecfidera said to be causing 'quasi-hysteria' among European MS patients). With Tecfidera now approaching what appears to be a critical ...

... ’s a revolution happening...and it’s going to change the way pharma thinks. As the accountable care movement gains traction in the United States and physicians eye a possible ... in the face of revolution, pharma must first understand the complete scope of the change now underway. In Pharma and the Changing US Payer Environment: Meeting the ...

... Key questions focus on how enthusiastically the guidelines will be embraced by physicians and how rapidly. In a note to ... the PCSK9 inhibitors, a number of analysts have pointed out, however, that initial ... inhibitors. This week’s Physician Views poll will ask US-based cardiologists, general practioners and ...

... Xeljanz to gain approval in Europe (see ViewPoints: Key opinion leader casts doubt as to whether Pfizer's Xeljanz ... Xeljanz's ability to inhibit progression of structural disease. FirstWord polled US-based rheumatologists in May to ascertain how physicians were utilising Xeljanz and this week's Physician Views ...

The collection includes the following reports: Market Access Canada Market Access in the EU5 – a comparative overview Value-based Key Account Management and the NHS – ensuring optimal performance under new rules Biosimilars in Emerging Markets

The collection includes the following reports: Pharma and Gamification: motivating positive outcomes – a primer The Impact of Mobile Health on Patient-Centric ... real-world commercial benefit from closed-loop marketing Driving Brand Value in Emerging Markets - winning strategies and tactics Big Data ...

The collection includes the following reports: MSL-KOL Engagement: delivering value under new rules Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value The Path to Product Inclusion in Clinical Guidelines: Strategies for Success ...

The collection includes the following reports: Charting the Biosimilar and Biobetter Development Pipeline (2013) Biosimilar Defensive Plays - assessing the options Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets (Volume 1 and Volume 2)

The collection includes the following reports: Inside China’s Pharma Sales Force – insights from the frontline Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets Driving Brand Value in Emerging Markets - winning strategies and tactics

The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains ... , products, late-stage pipeline drugs, product positioning, in the context of COPD market trends. Event Bulletins Benefit from the latest KOL ...

... be done to improve how these predictive tools can be used? This week's Physician Views poll asks oncologists based in the US and 5EU markets: How many cancer patients they assess with a companion diagnostic prior to treatment? How the ...

... demonstrated when administered in combination with statin therapy. Given the entrenchment (and genericisation) of most statin therapies, coupled with the subcutaneous ... potential for the emergent PCSK9 inhibitor class. This week's Physician Views poll asks US and 5EU-based cardiologists and general ...

... the second pharmacy benefits manager to do so (after CVS Caremark) - see Physician Views Poll Results – US Pulmonologists keen for Breo Ellipta – can payers ... device. This week's Physician Views poll asks pulmonologists and general practitioners based in the US and 5EU markets (where a substitutable generic version of Advair ...

... or ribavirin, thus significantly reducing side-effect burden. A Physician Views poll run by FirstWord in December 2012 (among 74 US-based gastroenterologists ... one-tablet combination of sofosbuvir and ledipasvir). But what of its commercial opportunity in the meantime, assuming the drug is launched in ...

The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in ... clinical opinion This new KOL Insight report Colorectal Cancer - EGFR inhibitors on the verge of growth provides everyone interested in this dynamic cancer sector with a complete ...

... that is, increasingly, transforming healthcare into ‘reality medicine’ that responds to the real world use of medicines rather than that prescribed by randomised controlled ... to pricing and positioning. How should pharma respond? In Strategies for Working with Real World Data, FirstWord makes a strong case for ...

... a cost of up to $1 billion. This week's Physician Views poll will look to assess whether initial KOL and analyst reaction to the top-line PREVAIL ... to prescribe enzalutamide (Xtandi) to on an off-label basis prior to approval? What characteristic would most influence you to prescribe enzalutamide (Xtandi) in ...

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary ... efficacious therapy, and continued uptake of existing therapies. Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and ...

... collectively as the ABCRs), which for many years were positioned as the gold standard therapies of choice - see Physician Views Poll Results – Neurologists ... analysts, which Novartis and Sanofi will no doubt do their best to rectify. Analysts at Barclays recently noted that 'importantly, the multiple sclerosis ...

... Ingelheim's Pradaxa was not a widely held view FirstWord Pharma PLUS subscribers can view the results and analysis from this poll ... . This week's FirstWord Physician Views poll will ask: How do the clinical profiles of oral anticoagulants compare with warfarin? How does the clinical profile ...

... of a combination Lantus/lixisenatide product, but commercial opportunity significant. Sanofi has previously demonstrated a willingness to shift its development strategy ... of Lantus in the long-acting insulin market. This week's Physician Views poll will ask endocrinologists and general practioners based in ...

... Sanofi securing European approval for its multiple sclerosis ... therapies (Gilenya, Aubagio and Tecfidera – yet to launch in Europe) providing comparable efficacy with greater convenience, there is ... patients using the drug developing PML. This week's Physician Views poll will ask neurologists based in the 5EU ( ...

... ; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma. Competition in the major ... market share from the gold standard treatments. ‘Therapy Trends: Diabetes’ is compiled from exclusive, in-depth interviews with the world’s leading ...

... centricity, patient empowerment, and closed-loop marketing (CLM). Innovations in Multichannel Marketing is a must-read for forward-thinking marketing and sales professionals. Key Benefits With ... a multichannel world for pharma.” – John Gerow, European multi-channel marketing director, AstraZeneca Innovations in Multichannel Marketing addresses your strategic and tactical questions, such as: What is multichannel marketing ...

... trials. Through The Impact of Mobile Health on Patient-Centric Disease Management, FirstWord explores the emerging and exciting world of mobile and digital health apps. Based ... , Boehringer Ingelheim. The Impact of Mobile Health on Patient-Centric Disease Management answers key questions: How can pharma harness the mobile and digital app ...